[Qiltrack AI] Shuttle Pharmaceuticals Holdings Inc (SHPH) 3-Minute Overview

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Shuttle Pharmaceuticals Holdings Inc (SHPH) 3-Minute Overview > **💡 One-Sentence Summary** > > Shuttle Pharmaceuticals is a tiny, clinical-stage biotech trying to improve cancer treatment (radiation therapy) and has just added an AI drug discovery platform, but it’s still pre-revenue and burning cash. > **📍 Basic Profile** > > Market Cap **$2.6M** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$3.85** --- > **⚡ 3 Things You Should Know** > > 1. ⚗️ **Pre-revenue, high-risk biotech:** There’s no meaningful revenue and ROE is around **-476%**, which basically means losses are huge relative to its tiny equity base—this is a pure “hope-and-research” play, not a cash-generating business. > > 2. 🧠 **Pivot toward AI drug discovery:** The recent acquisition of **Molecule.ai**, an AI molecular discovery platform, suggests Shuttle wants to ride the AI-in-healthcare wave—this can create a “hot story,” but also adds execution and focus risk for such a small company. > > 3. 🎢 **Micro-cap + huge volatility:** Market cap is only about **$2.6M**, the stock is down massively from a 52-week high of **$25.25** but jumped **+136% today**—this is the kind of name where sentiment, headlines, and financing news can move the price far more than fundamentals. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |------------------|---------------------|---------| > | Profitability | Weak👎 | Deep losses (ROE ~ -476%, ROA ~ -364%), negative cash flow per share (-$0.36 TTM); no sustainable earnings yet. | > | Growth Rate | Slow🐢 | No reliable revenue or EPS growth data—typical early-stage biotech still in R&D, not growth mode on sales. | > | Financial Health | Moderate💛 | Current ratio ~1.66 and quick ratio ~1.25 are okay, but debt/equity ~1.23 and negative interest coverage (-14.6x) mean it depends on external funding. | > | Valuation | Speculative | No PE (no earnings). PB ~4.4x for a tiny, loss-making micro-cap—pricing is mainly about future hopes, not current numbers. | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Develops cancer-focused therapies (especially to enhance radiation treatment) and now AI-enabled drug discovery tools, with the goal of eventually making money from drug approvals, partnerships, and licensing—but today it’s basically an R&D project funded by investors. **Revenue Breakdown:** | Business | Share | Trend | Comment | |-------------------------------------|-------|-------|---------| | Oncology drug R&D / candidate pipeline | [Data unavailable] | → | Likely no commercial revenue yet; spending is on clinical and preclinical development. | | AI drug discovery (Molecule.ai) | [Data unavailable] | New | Just acquired; potential for licensing or collaboration revenue later, but currently more cost than income. | *(No detailed revenue split is reported—this is standard for very early-stage biotechs.)* **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |------------|--------------|-------------|----------------| | Gross Margin | [Data unavailable] | [Data unavailable] | No meaningful sales, so margin data doesn’t really tell us much yet. | | Net Margin | [Data unavailable] | Below Average | The extreme negative ROE/ROA implies very heavy losses versus size; margins would be deeply negative. | | ROE | **-476%** | Far Below Average | Losses are huge relative to shareholder equity—this reflects constant cash burn and a very small capital base. | In other words, this is not about profitability yet; it’s about whether R&D eventually leads to a valuable drug or technology. --- #### 📈 How’s the Growth? **Growth Assessment:** More “development-stage” than “growth” stock—no clear revenue growth trend, only growth in R&D activity and possibly in the story (AI acquisition). | Metric | Latest | vs Last Year | Trend | |-----------------|-------------------|-------------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** Right now, “growth” is about expanding the pipeline and tech base (adding AI capabilities), not about growing sales or profits. Any future revenue, if it comes, will likely be lumpy—driven by milestones, licensing deals, or a successful product, not steady quarter-on-quarter growth. --- #### 💰 Financial Health Check **One Sentence:** Think of a person with a modest bank balance, a decent buffer for the next few months, a sizable short-term loan, and no stable salary yet—fine for now, but will likely need to borrow more or find new investors. | Metric | Value | Safe Zone | Assessment | |--------------------|----------------------|---------------|-----------| | Debt Ratio (est.) | ~55% (from D/E 1.23) | <60% safe | ✅Safe on this simple metric, but keep in mind it’s a tiny company with volatile equity. | | Current Ratio | **1.66** | >1.5 healthy | ✅Safe – Can likely cover short-term obligations for now. | | Quick Ratio | **1.25** | >1.0 basic | ✅Safe – Short-term liquid assets appear to cover current liabilities, but not by a huge margin. | | Interest Coverage | **-14.6x** | >3x | 🚨Dangerous – Operating losses mean they’re not covering interest from operations. | | Cash Flow | **-0.36/share TTM** | >0 | 🚨Negative – Cash burn; will likely need more capital raises if R&D continues. | So financially: not on the brink today, but structurally dependent on future fundraising (equity or debt), which can dilute shareholders. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$1.26** - 52-Week High: **$25.25** - Current: **$3.85** — closer to the low end, but remember: it has already crashed from much higher levels and just spiked +136% in one day. Position in range ≈ **11%** from the low (so “cheap zone” in pure 52-week terms, but that doesn’t mean low risk). | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ● (~11%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |-------------------|------------------------|---------------------------|------------| | vs Own History | PE: N/A (no earnings) | 5-year avg: [Data unavailable] | Can’t compare by PE; stock has been wildly volatile. | | vs Peers | PE: N/A | Industry avg: [Data unavailable] | Typical early-stage biotech: value is all about optionality, not current multiples. | | Other Metric | PB ~**4.4x** | Biotech small-cap often ~2–5x (very rough) | Toward the higher side for a loss-making micro-cap—investors are paying for “what might be,” not “what is.” | **What the Current Valuation is Betting On:** Basically, the market is betting that: - Shuttle’s cancer and radiation-related programs will make real clinical progress, **and/or** - the new AI platform (Molecule.ai) will either bring deals, partnerships, or make the pipeline much more valuable. If neither happens and they keep diluting to fund R&D, today’s price can still go lower despite already being far from the peak. --- #### 📰 Any Recent News? | Date (2025) | Event | Impact | |-------------|-------|--------| | Nov 21, 2025 | Completed acquisition of **Molecule.ai**, an AI company focused on molecular discovery and drug development technologies. | **Positive / Speculative** – Strengthens the “AI + biotech” story and could help pipeline discovery, but also adds integration risk and likely increases costs for a company that’s already very small. | No recent data on earnings, analyst targets, or insider trading were provided, which is common for names this small. --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |------------|------------------|------------------|------------------|--------------| | Gross Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | [Data unavailable] | [Data unavailable] | [Data unavailable] | Likely deeply negative each year. | | ROE | **-476% (TTM)** | [Data unavailable] | [Data unavailable] | Loss-making, no sign of profitability yet. | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |---------------|------------------|------------------|------------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | No clear revenue base; development stage. | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | Likely persistent losses as R&D ramps. | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | EPS likely negative and volatile with financing events. | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [Most Recent] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Previous | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Previous | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Previous | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Earnings Trend Interpretation:** No usable data, and for a micro-cap clinical-stage biotech, the exact EPS number each quarter matters far less than cash runway, trial progress, and financing plans. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |----------------|-------|------------| | Strong Buy/Buy | 0 | 0% | | Hold | 0 | 0% | | Sell | 0 | 0% | *(No analyst coverage reported—typical for such a small, early-stage company.)* **Target Price:** [Data unavailable] **vs Current Price:** [Data unavailable] **Insider Activity:** Net insider buying/selling data over the past 3 months: [Data unavailable] Without clear analyst or insider signals, price is mostly driven by retail sentiment, news bursts, and financing events. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Clinical & regulatory risk:** As with any small biotech, there’s a real chance that its drug candidates or approaches to improving radiation therapy simply don’t work well enough in clinical trials or fail to get regulatory approval → this could leave the company with ongoing losses and no viable commercial product. 2. **Financing & dilution risk:** With negative cash flow and no earnings, Shuttle will likely need to raise more capital via equity or other means → that can significantly dilute existing shareholders and pressure the stock, especially if done at lower prices. 3. **Execution & “AI pivot” risk:** Integrating Molecule.ai and actually turning AI capabilities into clinically meaningful, partnered, or monetizable assets is hard → if AI remains more of a buzzword than a real value driver, the market could lose interest, and the stock could give back recent speculative gains. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Shuttle Pharmaceuticals is a nano-cap, clinical-stage oncology biotech now combining cancer-focused R&D with an AI-driven molecular discovery platform. > **Key strength:** Its upside is entirely about optionality—if its radiation-related therapies or AI platform lead to a strong partnership or clinical success, the current tiny market cap leaves room for big percentage moves. > **Key risk:** It’s loss-making, pre-revenue, and dependent on future financing, so if clinical progress disappoints or funding becomes hard, shareholders face real dilution and potentially large losses. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis